Zevra Therapeutics (ZVRA) – Investment Analysts’ Weekly Ratings Updates

by · The Markets Daily

Several analysts have recently updated their ratings and price targets for Zevra Therapeutics (NASDAQ: ZVRA):

  • 6/23/2026 – Zevra Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $26.00 price target on the stock.
  • 6/10/2026 – Zevra Therapeutics had its price target raised by Guggenheim from $25.00 to $29.00. They now have a “buy” rating on the stock.
  • 6/10/2026 – Zevra Therapeutics had its price target raised by Maxim Group from $25.00 to $35.00. They now have a “buy” rating on the stock.
  • 6/9/2026 – Zevra Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $24.00 to $29.00. They now have a “buy” rating on the stock.
  • 6/9/2026 – Zevra Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
  • 6/9/2026 – Zevra Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
  • 6/9/2026 – Zevra Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $27.00 price target on the stock, up from $23.00.
  • 6/9/2026 – Zevra Therapeutics had its price target raised by Citizens Jmp from $18.00 to $25.00. They now have a “market outperform” rating on the stock.
  • 6/8/2026 – Zevra Therapeutics had its price target raised by Cantor Fitzgerald from $24.00 to $34.00. They now have an “overweight” rating on the stock.
  • 6/6/2026 – Zevra Therapeutics was downgraded by Wall Street Zen from “buy” to “hold”.
  • 5/22/2026 – Zevra Therapeutics was downgraded by Weiss Ratings from “buy (b-)” to “hold (c)”.
  • 5/8/2026 – Zevra Therapeutics was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
  • 5/8/2026 – Zevra Therapeutics had its price target raised by Guggenheim from $23.00 to $25.00. They now have a “buy” rating on the stock.

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

See Also